Kymera Therapeutics, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	10-K	S-1/A
Revenues	46.8	72.8	34.0	2.9	17.7
Revenue growth	-35.7%	114.0%	1060.0%	-83.4%
Cost of goods sold	0.0	0.0	0.0	0.0	35.4
Gross profit	46.8	72.8	34.0	2.9	-17.7
Gross margin	100.0%	100.0%	100.0%	100.0%	-100.0%
Selling, general and administrative [+]	208.1	173.4	80.3	45.1	3.8
General and administrative					3.8
Other operating expenses	0.2	0.2	0.1	0.0
EBITDA [+]	-158.5	-98.3	-44.7	-41.4	-21.2
EBITDA growth	61.2%	120.1%	7.8%	95.0%
EBITDA margin	-338.4%	-135.0%	-131.2%	-1411.9%	-120.2%
Depreciation and amortization	3.0	2.4	1.8	0.8	0.2
EBIT [+]	-161.4	-100.7	-46.4	-42.3	-21.5
EBIT growth	60.3%	116.9%	9.9%	97.0%
EBIT margin	-344.7%	-138.3%	-136.4%	-1440.0%	-121.3%
Interest expense					0.0
Interest expense					0.0
Other income (expense), net [+]	6.6	0.5	0.8	1.0
Other non-operating income	6.6	0.5	0.8	1.0
Other	6.6	0.5	0.8	1.0
Pre-tax income	-154.8	-100.2	-45.6	-41.2	-21.5
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-154.8	-100.2	-45.6	-41.2	-21.5
Net margin	-330.6%	-137.6%	-134.0%	-1405.8%	-121.4%

Basic EPS [+]	($2.87)	($2.09)	($2.63)	($24.28)	($18.26)
Growth	37.4%	-20.5%	-89.2%	33.0%
Diluted EPS [+]	($2.87)	($2.09)	($2.63)	($24.28)	($18.26)
Growth	37.4%	-20.5%	-89.2%	33.0%

Shares outstanding (basic) [+]	53.9	48.0	17.3	1.7	1.2
Growth	12.4%	176.6%	921.5%	44.5%
Shares outstanding (diluted) [+]	53.9	48.0	17.3	1.7	1.2
Growth	12.4%	176.6%	921.5%	44.5%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.